TMEM106B

TMEM106B

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TMEM106B</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[TMEM106B](/genes/tmem106b)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9NUM4" target="_blank">Q9NUM4</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>31 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Late endosomes and lysosomes</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Type II lysosomal transmembrane protein family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Frontotemporal Dementia](/diseases/ftd), [ALS](/diseases/als), [LATE](/diseases/late-encephalopathy)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">164 edges</a></td>
</tr>
</table>

TMEM106B

TMEM106B

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">TMEM106B</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[TMEM106B](/genes/tmem106b)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9NUM4" target="_blank">Q9NUM4</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>31 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Late endosomes and lysosomes</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Type II lysosomal transmembrane protein family</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Frontotemporal Dementia](/diseases/ftd), [ALS](/diseases/als), [LATE](/diseases/late-encephalopathy)</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">164 edges</a></td>
</tr>
</table>

TMEM106B

TMEM106B (Transmembrane Protein 106B) is a 323-amino acid type II lysosomal transmembrane protein encoded by the [TMEM106B](/genes/tmem106b) gene on chromosome 7p21.1. Originally identified as a genetic risk factor for [frontotemporal lobar degeneration](/diseases/frontotemporal-dementia) (FTLD) through genome-wide association studies, TMEM106B has emerged as a critical regulator of lysosomal function with implications for multiple neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis](/diseases/als) [@common2010].

Gene and Protein Structure

The TMEM106B gene spans approximately 17 kb and consists of 9 exons. The protein localizes primarily to the membrane of late endosomes and lysosomes, where it exists as a homodimer. Structural studies indicate that TMEM106B contains a short N-terminal cytoplasmic domain (approximately 10 amino acids), a single transmembrane helix, and a large C-terminal luminal domain that faces the interior of lysosomes [@uniprot].

The TMEM106B protein exhibits several distinctive features:

• Molecular weight: Approximately 31 kDa
• Topology: Type II transmembrane protein (N-out, C-in)
• Oligomerization: Forms homodimers and higher-order oligomers
• Post-translational modifications: N-glycosylation in the luminal domain
• Tissue distribution: Highest expression in brain, particularly in neurons and microglia

Lysosomal Biology

TMEM106B functions as a master regulator of lysosomal function, affecting multiple aspects of lysosomal biology that are critical for neuronal health [@vanmechelen2019]:

Lysosomal Acidification and Hydrolase Activity

Proper lysosomal function requires an acidic interior (pH 4.5-5.0) maintained by v-type ATPases. TMEM106B contributes to:

• Ion homeostasis: Regulation of proton pump assembly
• Hydrolase activation: Optimal pH for cathepsin proteases
• Cargo degradation: Efficient breakdown of proteins, lipids, and nucleic acids

Membrane Trafficking

TMEM106B influences endosomal-lysosomal trafficking through:

• Late endosome maturation: Coordination of cargo sorting
• Lysosomal movement: Regulation of motor protein interactions
• Membrane fusion: ESCRT-dependent and independent pathways

Autophagy Regulation

A critical function of TMEM106B is its role in autophagy, the cellular recycling system that degrades damaged organelles and protein aggregates:

Genetic Variants and Disease Risk

GWAS Discovery and Replication

The TMEM106B locus was first identified as a major risk factor for FTLD in a landmark genome-wide association study that identified the single nucleotide polymorphism (SNP) rs1990620 on chromosome 7p21 [@common2010]. This finding has been replicated in multiple independent cohorts and expanded to include:

• rs3173615 (T185S): The key amino acid change distinguishing risk alleles
• Haplotypic structure: Multiple independent signals at the locus
• Ancestral effects: Population-specific allele frequencies

The T185S Functional Polymorphism

The amino acid substitution threonine to serine at position 185 (T185S) represents the most functionally significant TMEM106B variant:

| Allele | Effect | Frequency (European) | Disease Association |
|--------|--------|---------------------|-------------------|
| T185 (protective) | Higher TMEM106B expression | ~40% | Reduced FTLD risk |
| S185 (risk) | Lower TMEM106B expression | ~60% | Increased FTLD risk, especially with GRN mutations |

Gene-Disease Interactions

TMEM106B acts as a powerful modifier of several monogenic neurodegenerative conditions:

Progranulin (GRN) Mutations

TMEM106B strongly modifies disease onset and phenotype in individuals with [GRN](/genes/grn) mutations:

• Age of onset: Risk alleles accelerate onset by 5-10 years
• Clinical phenotype: Influences presentation (behavioral vs. language variant)
• TDP-43 pathology: Modifies burden and distribution of TDP-43 inclusions [@schwenk2014]

C9orf72 Expansions

The hexanucleotide repeat expansion in [C9orf72](/genes/c9orf72) represents the most common genetic cause of FTLD/ALS. TMEM106B risk variants:

• Modify disease penetrance: Earlier onset in carriers of both risk factors
• Affect lysosomal function: Synergistic effects on endolysosomal pathways [@cm2024]
• Influence clinical phenotype: Bias toward ALS phenotype with risk alleles

TMEM106B and TDP-43 Pathology

A central finding in TMEM106B biology is its relationship with TDP-43 proteinopathy, the characteristic pathological hallmark of most FTLD subtypes and ALS [@finch2011]:

TDP-43 Biology

TAR DNA-binding protein 43 (TDP-43) is a nuclear RNA-binding protein that:

• Regulates RNA splicing, transport, and translation
• Forms stress granules under cellular stress
• Aggregates in pathological inclusions in FTLD and ALS

TMEM106B-TDP-43 Interactions

Therapeutic Implications

Understanding the TMEM106B-TDP-43 relationship has opened several therapeutic avenues:

• Gene therapy: Increase TMEM106B expression to enhance lysosomal function
• Small molecules: Enhance lysosomal acidification and function
• TDP-43 targeting: Indirect effects through improved cellular clearance

Interaction with Other Neurodegeneration Proteins

Progranulin (PGRN)

TMEM106B and progranulin have a complex genetic and functional relationship [@brett2022]:

• Genetic: TMEM106B modifies PGRN-FTD phenotype
• Protein-protein interaction: Direct physical binding
• Lysosomal colocalization: Both proteins traffic through endolysosomal system
• Functional compensation: TMEM106B may partially compensate for reduced PGRN

CHMP2B

Mutations in CHMP2B cause a rare form of FTLD (FTD-3). TMEM106B associates with CHMP2B as part of the ESCRT-III complex involved in membrane remodeling [@cm2015].

Beta-amyloid and Tau

Emerging evidence links TMEM106B to [Alzheimer's disease](/diseases/alzheimers-disease) pathology:

• Amyloid interaction: TMEM106B expression affected by [amyloid-beta](/proteins/amyloid-beta) accumulation
• Tau pathology: TMEM106B variants influence tau burden in AD brain
• Microglial modulation: Effects on microglial lysosomal function

Cell-Type Specific Effects

Neurons

TMEM106B is highly expressed in neurons where it:

• Maintains neuronal lysosomal function
• Protects against proteotoxic stress
• Supports dendritic and axonal health
• Regulates synaptic vesicle trafficking

Microglia

Microglial TMEM106B affects:

• Inflammatory responses: Lysosomal function in immune activation
• Phagocytosis: Clearance of debris and protein aggregates
• Aging effects: Age-related changes in microglial lysosomes

Oligodendrocytes

Myelinating oligodendrocytes require TMEM106B for:

• Myelin maintenance: Lysosomal function in myelin turnover
• Energy metabolism: Support for highly metabolic cells

Biomarker Potential

TMEM106B has significant potential as a biomarker for neurodegenerative disease:

Genetic Biomarkers

• Risk stratification: TMEM106B genotyping for family risk assessment
• Predictive testing: Age of onset prediction in GRN mutation carriers
• Patient selection: Enrichment for clinical trials

Fluid Biomarkers

• Blood TMEM106B: Correlates with disease status and progression
• CSF TMEM106B: Emerging as a potential diagnostic marker
• Combination panels: TMEM106B with other lysosomal proteins

Imaging Biomarkers

• PET ligands: Development of TMEM106B-specific imaging agents
• MRI correlations: TMEM106B risk variants associate with cortical atrophy patterns [@nichols2015]

Therapeutic Strategies

Gene Therapy Approaches

• Viral vectors: AAV-mediated TMEM106B overexpression
• Conditional expression: Cell-type specific delivery
• Allele-specific: Targeting protective alleles

Small Molecule Modulators

• Lysosomal function enhancers: Improve acidification and hydrolase activity
• TFEB agonists: Activate lysosomal biogenesis via mTOR inhibition
• Autophagy inducers: Enhance cellular clearance pathways

Combination Approaches

• Dual targeting: TMEM106B + progranulin modulation
• Multimodal therapy: Gene therapy + small molecules
• Disease-modifying combinations: Address multiple pathways

TMEM106B in Other Neurological Conditions

Parkinson's Disease

Emerging evidence links TMEM106B to [Parkinson's disease](/diseases/parkinsons-disease):

• Genetic association: PD risk variants near TMEM106B locus
• Lysosomal dysfunction: Central to PD pathogenesis
• Alpha-synuclein interaction: Effects on [alpha-synuclein](/proteins/alpha-synuclein) clearance [@lynch2019]

Normal Aging

TMEM106B expression changes with age:

• Age-related decline: Reduced expression in aged brain
• Cognitive effects: TMEM106B variants affect cognitive trajectories
• Vulnerability: Age-related changes unmask disease effects

Animal Models and Experimental Systems

Mouse Models

• Tmem106b knockout: Lethal prenatally, highlighting essential function
• Transgenic overexpression: Rescue of lysosomal phenotypes
• Humanized mice: Expressing human TMEM106B variants

Cell Culture Models

• iPSC-derived neurons: Patient-specific TMEM106B variants
• Microglia: Role in neuroinflammation
• Organoids: Brain organoid models of TMEM106B dysfunction

Research Challenges and Future Directions

See Also

• [Genes Index](/genes)
• [Frontotemporal Dementia](/diseases/frontotemporal-disease)
• [ALS](/diseases/als)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)
• [Progranulin](/genes/grn)
• [C9orf72](/genes/c9orf72)
• [Microglia](/cell-types/microglia)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving TMEM106B discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving TMEM106B discovered through SciDEX knowledge graph analysis: